These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 11839653)

  • 1. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
    Peck RA; Hewett J; Harding MW; Wang YM; Chaturvedi PR; Bhatnagar A; Ziessman H; Atkins F; Hawkins MJ
    J Clin Oncol; 2001 Jun; 19(12):3130-41. PubMed ID: 11408511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
    Gandhi L; Harding MW; Neubauer M; Langer CJ; Moore M; Ross HJ; Johnson BE; Lynch TJ
    Cancer; 2007 Mar; 109(5):924-32. PubMed ID: 17285598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.
    Pisters PW; Patel SR; Prieto VG; Thall PF; Lewis VO; Feig BW; Hunt KK; Yasko AW; Lin PP; Jacobson MG; Burgess MA; Pollock RE; Zagars GK; Benjamin RS; Ballo MT
    J Clin Oncol; 2004 Aug; 22(16):3375-80. PubMed ID: 15310783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
    Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
    Seiden MV; Swenerton KD; Matulonis U; Campos S; Rose P; Batist G; Ette E; Garg V; Fuller A; Harding MW; Charpentier D
    Gynecol Oncol; 2002 Sep; 86(3):302-10. PubMed ID: 12217752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
    Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
    Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
    Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa.
    Toma S; Canavese G; Grimaldi A; Ravera G; Ugolini D; Percivale P; Badellino F
    Oncol Rep; 2003; 10(3):641-7. PubMed ID: 12684637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
    Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
    Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.